基于吉西他滨的化疗方案联合抗CD20单抗对复发性弥漫大B细胞淋巴瘤患儿临床相关指标及预后的影响  

Effect of Gemcitabine Based Chemotherapy Regimen Combined with Anti-CD20 Monoclonal Antibody on Clinical Related Indexes and Prognosis of Children with Recurrent Diffuse Large B-cell Lymphoma

作　　者：姚海娜 黄闪 YAO Hai-na;HUANG Shan(Department of Hematology and Oncology Post,Henan Children's Hospital,Zhengzhou 450018,Henan Province,China)

机构地区：[1]河南省儿童医院血液肿瘤科,河南郑州450018

出　　处：《罕少疾病杂志》2023年第3期93-94,共2页Journal of Rare and Uncommon Diseases

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20200670)。

摘　　要：目的探讨基于吉西他滨的化疗方案联合抗CD20单抗治疗复发性弥漫大B细胞淋巴瘤(DLBCL)患儿的效果。方法回顾性分析2018年1月至2019年1月该院诊治的74例复发性DLBCL患儿的病历资料,按治疗方式的不同分为两组,采用基于吉西他滨的化疗方案(吉西他滨+顺铂+地塞米松)的37例患者为对照组,采用基于吉西他滨的化疗方案联合抗CD20单抗(利妥昔单抗)治疗的37例患者为观察组。21d为1个周期,共治疗4个周期,并于治疗后随访3年。对比两组临床疗效、相关指标阳性表达率、不良反应、生存率。结果观察组治疗总有效率[94.59%(35/37)]高于对照组[78.38%(29/37)],有统计学差异(P<0.05);治疗前,两组叉头框蛋白P1(FOXP1)、B细胞淋巴瘤因子-6(Bcl-6)阳性表达率对比,无统计学差异(P>0.05);治疗后,观察组FOXP1阳性表达率[21.62%(8/37)]低于对照组[54.05%(20/37)],Bcl-6阳性表达率[78.38%(29/37)]高于对照组[51.35%(19/37)],有统计学差异(P<0.05);两组不良反应相当,无统计学差异(P>0.05);观察组生存率[64.86%(24/37)]高于对照组[40.54%(15/37)],有统计学差异(P<0.05)。结论基于吉西他滨的化疗方案联合抗CD20单抗治疗复发性DLBCL患儿效果确切,可有效改善临床相关指标,提高生存率,且无严重不良反应,临床应用价值较高。Objective To investigate the effect of gemcitabine based chemotherapy regimen combined with anti-CD20 monoclonal antibody on children with recurrent diffuse large B-cell lymphoma(DLBCL).Methods The medical records of 74 children with recurrent DLBCL diagnosed and treated in our hospital from January 2018 to January 2019 were retrospectively analyzed.According to the different treatment methods,they were divided into two groups.37 patients with gemcitabine based chemotherapy regimen(gemcitabine+cisplatin+dexamethasone)were used as the control group,and 37 patients with gemcitabine based chemotherapy regimen combined with anti-CD20 monoclonal antibody(rituximab)were used as the observation group.21 days was one cycle,with a total of 4 cycles of treatment.The patients were followed up for 3 years after treatment.The clinical efficacy,positive expression rate of related indicators,adverse reactions and survival rate were compared between the two groups.Results The total effective rate of the observation group[94.59%(35/37)]was higher than that of the control group[78.38%(29/37)],with statistical difference(P<0.05);Before treatment,the positive expression rates of forkhead box protein P1(FOXP1)and B-cell lymphoma factor-6(bcl-6)were not significantly different between the two groups(P>0.05);After treatment,the positive expression rate of FOXP1 in the observation group[21.62%(8/37)]was lower than that in the control group[54.05%(20/37)],and the positive expression rate of bcl-6[78.38%(29/37)]was higher than that in the control group[51.35%(19/37)],with statistical difference(P<0.05);The adverse reactions of the two groups were similar,and there was no statistical difference(P>0.05);The survival rate of the observation group[64.86%(24/37)]was higher than that of the control group[40.54%(15/37)],with statistical difference(P<0.05).Conclusion Gemcitabine based chemotherapy regimen combined with anti-CD20 monoclonal antibody is effective in the treatment of recurrent DLBCL children,which can effectively improve the clinica

关 键 词：复发性弥漫大B细胞淋巴瘤 吉西他滨 临床疗效 不良反应 

分 类 号：R557.4[医药卫生—血液循环系统疾病]